BERNETT MATTHEW J has a total of 15 patent applications. Its first patent ever was published in 2006. It filed its patents most often in United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals and biotechnology are AFFIMED THERAPEUTICS AG, APEXIGEN INC and LAVA THERAPEUTICS B V.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 12 | |
#2 | WIPO (World Intellectual Property Organization) | 3 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Bernett Matthew J | 15 |
#2 | Desjarlais John R | 14 |
#3 | Lazar Gregory Alan | 9 |
#4 | Karki Sher Bahadur | 9 |
#5 | Pong Erik Weiking | 6 |
#6 | Richards John O | 6 |
#7 | Zhukovsky Eugene Alexander | 6 |
#8 | Chu Seung Yup | 6 |
#9 | Nguyen Duc-Hanh Thi | 4 |
#10 | Moore Gregory | 3 |
Publication | Filing date | Title |
---|---|---|
WO2011106707A2 | Antibodies that specifically bind to dr3 | |
WO2009129538A2 | Human equivalent monoclonal antibodies engineered from nonhuman variable regions | |
US2008199471A1 | Optimized cd40 antibodies and methods of using the same | |
US2009162382A1 | Optimized ca9 antibodies and methods of using the same | |
US2008254027A1 | Optimized CD5 antibodies and methods of using the same | |
US2008219974A1 | Optimized antibodies that target hm1.24 | |
US2008260731A1 | Optimized antibodies that target cd19 | |
WO2007008937A2 | Adiponectin variants |